Transsphenoidal surgery for prolactinomas: results and prognosis

Abstract

Objective. The aim of this study was to explore the long-term outcomes of surgery for transsphenoidal prolactinomas and the factors that influence them. Material and methods. Transsphenoidal approach for pituitary adenomas has been applied to 329 patients in the Department of Neurosurgery of Kaunas University of Medicine Hospital in the period of 1995 to 2006. Of these, 85 patients were operated for prolactinomas. Results. Of the 85 patients operated on for prolactinomas, 68 (80%) were females and 17 (20%) were males. Thirty-two microprolactinomas and 36 macroprolactinomas were diagnosed in women and 16 and 1, respectively, in men. Twenty (23.5%) patients (16 women and 4 men) had visual field defects before the operation. Dopamine agonist therapy was administered in 50 patients (38 women and 12 men) before the operation. Of 10 women, in whom microadenoma was diagnosed and no dopamine agonist therapy was prescribed, remission was achieved in 9 (90%) patients after the operation, while of 22 women, who was treated with dopamine agonists before the operation, remission was achieved only in 10 (45.5%) (P=0.01). Each year of age decreased the chance of remission by 8%. Conclusions. Remission after the surgical treatment was achieved in 11.8% of men and 47.1% of women hyperprowith prolactinomas. Remission rate was very high (90%) among women with microprolactinoma not treated with dopamine agonist before the surgical treatment. The probability of a good outcome of surgery among women with prolactinoma was related to younger age of the patient, noninvasive tumor growth, plasma prolactin level less than 2309 mU/L, and no use of dopamine agonist before the surgical treatment.

Trans-Sphenoidal Surgery in Prolactin Secreting Pituitary Tumors: A Long-Term Referral Center Experience.

“…Our results are similar to previous reports, as remission rate after surgery is reported in around 80% of micro-PRL-omas and in around 40% of macro-PRL-omas ( [12][13][14][15][16][17][18][19][20][21][22][23][24] ).…”

Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors

“…This latter instance was particularly fitting for women of childbearing age, in whom obtaining a surgical cure avoided a lengthy medical treatment potentially interfering with pregnancy. Our evidence is in line with what has been published by high-volume centers [10,[16][17][18][19][20][21][22][23][24][25][26][27]: TSS is linked to low surgical complications and a remission rate of about 80% and 40%, respectively, for micro-and macroprolactinomas. Consistently, Andereggen et al [28] showed that, at 10 years follow-up, the control of hyperprolactinemia required DA agonist therapy in 32% of patients who underwent primary surgical therapy and in 64% of patients who received primary medical therapy and that primary surgical therapy is a protective factor for long-term treatment with DA.…”

Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors.

“…Our evidences are in line with what published by high-volume centers [10,[16][17][18][19][20][21][22][23][24][25][26][27]: TSS is linked to low surgical complications, and a remission rate of about 80% and 40% respectively for micro and macroprolactinomas. Consistently, Andereggen et al [28] showed that at 10 years follow-up, the control of hyperprolactinaemia required DA-agonist therapy in 32% of patients who underwent primary surgical therapy and in 64% of patients who had primary medical therapy and that the primary surgical therapy is a protective factor for long-term treatment with DA.…”